<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697850</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1715</org_study_id>
    <secondary_id>2018-001807-35</secondary_id>
    <nct_id>NCT03697850</nct_id>
  </id_info>
  <brief_title>Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy</brief_title>
  <acronym>BladderSpar</acronym>
  <official_title>Phase II Study of Maintenance Anti-PD-L1 Treatment With Atezolizumab After Chemo-radiotherapy for Muscle-infiltrating Bladder Cancer Patients Not Eligible for Radical Cystectomy: Bladder Sparing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients older than ≥18 years, with muscle-invasive bladder cancer unfit for radical&#xD;
      cystectomy because of age, comorbidities, and/or patient's refusal.&#xD;
&#xD;
      This study is designed as a multicentre, single-arm phase II study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
    <description>Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>Local control rate will be evaluated by cystoscopy. The presence of non-muscle-invasive or muscle-invasive bladder cancers will be considered as a local failure. To be defined as locally controlled, the bladder must be completely free of tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease Free Survival is defined as the delay between date of inclusion and tumour relapse (local, regional, or distant) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival is defined as the delay between the date of inclusion and the date of death, from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>The tolerance and safety will be evaluated by toxicity (acute [&lt;6 months after the start of atezolizumab] and late [≥6 months after the start of atezolizumab]), assessed using the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>The tolerance and safety will be evaluated by toxicity (acute [&lt;6 months after the start of atezolizumab] and late [≥6 months after the start of atezolizumab]), assessed using the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Cancer Patients (QLQ-C30)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Bladder Cancer Muscle Invasive (QLQ-BLM30)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Core Questionnaire - Elderly Cancer Patients (QLQ-ELD14)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>G8 oncodage</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy</description>
    <arm_group_label>atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selection phase&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Muscle-invasive bladder cancer (MIBC) pT2-T3 histologically confirmed:&#xD;
&#xD;
             Urothelial and squamous cell histological types are allowed. De novo MIBC or after a&#xD;
             history of non-muscle-invasive bladder cancer.&#xD;
&#xD;
          2. Complete transurethral resection of bladder tumour (TURBT), either:&#xD;
&#xD;
             within 6 weeks of selection if no chemotherapy was administered, or before starting&#xD;
             chemotherapy.&#xD;
&#xD;
          3. Patients for which chemo-radiotherapy is planned&#xD;
&#xD;
          4. No major pelvic involvement: pelvic nodes ≤15 mm on CT scan.&#xD;
&#xD;
          5. No distant metastasis.&#xD;
&#xD;
          6. Patient unfit for radical cystectomy because of age, comorbidities, or patient's&#xD;
             refusal.&#xD;
&#xD;
          7. Patients ≥18 years old&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.&#xD;
&#xD;
          9. Life expectancy ≥12 months.&#xD;
&#xD;
         10. Haematological and biological parameters:&#xD;
&#xD;
             White blood cell count ≥4000/mm³ Platelet count ≥100000 cells/mm³ Haemoglobin level ≥9&#xD;
             g/dL or corrected after transfusion Adequate renal function: clearance &gt;50 mL/min&#xD;
             (Cockcroft). Adequate hepatic function: Aspartate aminotransferase (AST [SGOT]) and&#xD;
             Alanine aminotransferase (ALT [SGPT]) ≤2.5 x upper limit of normal (ULN), or ≤3.5 x&#xD;
             ULN in the case of concurrent disease with known etiology and for which a corrective&#xD;
             treatment is possible.&#xD;
&#xD;
         11. Patients of childbearing potential who agree to use a medically acceptable method of&#xD;
             contraception during the study and for 120 days after the last study treatment. Women&#xD;
             must have a negative urine or serum pregnancy test before receiving the study&#xD;
             treatment and within 14 days prior to selection.&#xD;
&#xD;
         12. Patients having provided written informed consent prior to any study-related&#xD;
             procedures.&#xD;
&#xD;
         13. Patients affiliated to the social security scheme.&#xD;
&#xD;
         14. Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures indicated in the protocol.&#xD;
&#xD;
         15. Patient consents to the use of their collected tumour specimen, as well as, blood&#xD;
             samples as detailed in the protocol for future scientific research which includes but&#xD;
             not limited to DNA, RNA, and protein-based biomarker detection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior pelvic irradiation.&#xD;
&#xD;
          2. MIBC histology other than urothelial or squamous cell carcinomas (e.g.,&#xD;
             adenocarcinomas, micropapillary, sarcomas, or small cell histological types).&#xD;
&#xD;
          3. History of neoplastic disease, during the 3 years before selection, except completely&#xD;
             resected cutaneous basal-cell carcinomas, carcinoma in-situ or localised prostate&#xD;
             cancer without biochemical recurrence following definitive treatment.&#xD;
&#xD;
          4. Prior treatment with CD137 agonists or immune checkpoint inhibitors, including&#xD;
             anti-cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4), anti-programmed&#xD;
             death-1 receptor (anti-PD-1), and anti-programmed death-ligand 1 (anti-PD-L1)&#xD;
             therapeutic antibodies.&#xD;
&#xD;
          5. Contraindications for pelvic radiotherapy (e.g., inflammatory bowel disease).&#xD;
&#xD;
          6. History of immunodeficiency, including HIV infection, or systemic steroid therapy for&#xD;
             any other disease.&#xD;
&#xD;
          7. A history of active autoimmune disease, except autoimmune-related hypothyroidism and&#xD;
             type I diabetes mellitus (see appendix 5).&#xD;
&#xD;
          8. History of severe allergic anaphylactic reactions to chimeric, human or humanised&#xD;
             antibodies, or fusion proteins.&#xD;
&#xD;
          9. Known hypersensitivity to Chinese hamster ovary (CHO) cell products or any component&#xD;
             of the atezolizumab formulation.&#xD;
&#xD;
         10. Prior allogeneic stem cell or solid organ transplant.&#xD;
&#xD;
         11. Patients with the following severe acute co-morbidity are not eligible:&#xD;
&#xD;
             Unstable angina or congestive heart failure that required hospitalisation in the 6&#xD;
             months before selection.&#xD;
&#xD;
             Transmural myocardial infarction in the 6 months prior to selection. Acute bacterial&#xD;
             or fungal infection requiring intravenous antibiotics at selection.&#xD;
&#xD;
             Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
             requiring hospitalisation or precluding study therapy at the time of selection.&#xD;
&#xD;
             Severe hepatic disease: Child-Pugh Class B or C.&#xD;
&#xD;
         12. Patients with any other disease or illness which requires hospitalisation or is&#xD;
             incompatible with the study treatment are not eligible.&#xD;
&#xD;
         13. Patients unable to comply with study obligations for geographic, social, or physical&#xD;
             reasons, or who are unable to understand the purpose and procedures of the study.&#xD;
&#xD;
         14. Patients enrolled in another therapeutic study within 30 days of selection.&#xD;
&#xD;
         15. Pregnant or breast feeding women.&#xD;
&#xD;
         16. Person deprived of their liberty or under protective custody or guardianship.&#xD;
&#xD;
        Inclusion phase&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have received standard (chemo)-radiotherapy ≥60 gray (Gy) or equivalent&#xD;
             on the bladder according to the local practice.&#xD;
&#xD;
          2. The first administration of atezolizumab must be performed 30 (+/-5) days after the&#xD;
             last session of radiotherapy (RT).&#xD;
&#xD;
          3. ECOG performance status ≤2.&#xD;
&#xD;
          4. Haematological and biological parameters:&#xD;
&#xD;
             White blood cell count ≥3000/mm³ Platelet count ≥100000 cells/mm³ Haemoglobin level ≥9&#xD;
             g/dL or corrected after transfusion Adequate renal function: clearance &gt;50 mL/min&#xD;
             (Cockcroft) Adequate hepatic function: AST (SGOT) and ALT (SGPT) ≤2.5 x ULN, or ≤3.5 x&#xD;
             ULN in the case of concurrent disease with known etiology and for which a corrective&#xD;
             treatment is possible.&#xD;
&#xD;
          5. Patients of childbearing potential who agree to use a medically acceptable method of&#xD;
             contraception during the study and for 120 days after the last study treatment. Women&#xD;
             must have a negative urine or serum pregnancy test before receiving the study&#xD;
             treatment and within 14 days prior to inclusion.&#xD;
&#xD;
          6. Patients having provided written informed consent prior to any study-related&#xD;
             procedures.&#xD;
&#xD;
          7. Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures indicated in the protocol.&#xD;
&#xD;
          8. Patient consents to the use of their collected tumour specimen, as well as, blood&#xD;
             samples as detailed in the protocol for future scientific research which includes but&#xD;
             not limited to DNA, RNA, and protein-based biomarker detection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The same non-inclusion criteria of the selection phase have to be respected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe HENNEQUIN, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra PELISSIER</last_name>
    <phone>+33 1 44 23 55 68</phone>
    <email>s-pelissier@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul SARGOS, MD</last_name>
      <phone>+33 5 56 33 33 43</phone>
      <email>p.sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève LOOS, MD</last_name>
      <phone>+33 4 73 27 81 42</phone>
      <email>genevieve.loos@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN, MD</last_name>
      <phone>+33 3 80 73 75 28</phone>
      <email>emartin@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PASQUIER, MD</last_name>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icm Val D'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David AZRIA, PhD</last_name>
      <phone>+33 4 67 61 31 32</phone>
      <email>david.azria@montpellier.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azureen de Cancerologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe RONCHIN, MD</last_name>
      <phone>+33 4 94 52 11 82</phone>
      <email>ronchinp@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Eve CHAND FOUCHE, MD</last_name>
      <phone>+33 4 92 03 12 61</phone>
      <email>marie-eve.chand@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN, PhD</last_name>
      <phone>+33 1 42 49 90 24</phone>
      <email>christophe.hennequin2@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan ROUPRÊT, PhD</last_name>
      <phone>+33 1 42 17 71 29</phone>
      <email>mroupret@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHAPET, PhD</last_name>
      <phone>+33 4 78 86 42 51</phone>
      <email>Olivier.chapet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>INSTITUT de CANCEROLOGIE DE L'OUEST - site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentine GUIMAS, MD</last_name>
      <phone>+33 2 40 57 99 55</phone>
      <email>Valentine.Guimas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel GEOFFROIS, MD</last_name>
      <phone>+33 3 83 59 83 32</phone>
      <email>l.geoffrois@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre BLANCHARD, MD</last_name>
      <phone>+331 42 11 44 13</phone>
      <email>pierre.blanchard@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

